FOLFOX6/FOLFOX7

PreclinicalSmall molecule

Institut de Recherches Internationales Servier

FOLFOX6/FOLFOX7 is one of 27 small molecule programs targeting Malignancies. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalignanciesRecruiting

MalignanciesPreclinical

Recruiting

Competition

Competitive Landscape

28 competitors in Malignancies

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

4 2

Fludara

Sanofi

Phase 2

4 3

Cellcept

Roche

Phase 2

2 4

Eloxatin

Teva

Phase 2

1 5

Prograf

VVeloxis Pharmaceuticals

Phase 2

2 6

Fluoropyrimidine

Roche

Phase 2

1 7

Gemzar

Johnson & Johnson

Phase 1

2 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

2 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

1 10

Tibsovo

SServier

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT05786924

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Recruiting· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Preclinical·NCT05786924·554 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FOLFOX6/FOLFOX7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX6/FOLFOX7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX6/FOLFOX7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut de Recherches Internationales Servier company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Institut de Recherches Internationales Servier

FOLFOX6/FOLFOX7

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News